Rationally designed protein subunit vaccines are being developed for a variety of viruses including influenza, RSV, SARS-CoV-2, and HIV. These vaccines are based on stabilized versions of the primary targets of neutralizing antibodies on the viral surface, namely, viral fusion glycoproteins. While these immunogens display the epitopes of potent neutralizing antibodies, they also present epitopes recognized by non-neutralizing or weakly neutralizing ("off-target") antibodies. Using our recently developed electron microscopy polyclonal epitope mapping approach, we have uncovered a phenomenon wherein off-target antibodies elicited by HIV trimer subunit vaccines cause the otherwise highly stabilized trimeric proteins to degrade into cognate pro...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
Rationally designed protein subunit vaccines are being developed for a variety of viruses including ...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
The high HIV-1 viral diversity is a formidable hurdle for the development of an HIV-1 vaccine. Elici...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
HIV-1 is a major threat to global health and a vaccine is not yet on the horizon. A successful HIV-1...
Characterizing polyclonal antibody responses via currently available methods is inherently complex a...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
Purpose of review To provide an update on the latest developments in the field of HIV-1 antibody-bas...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
Rationally designed protein subunit vaccines are being developed for a variety of viruses including ...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
The high HIV-1 viral diversity is a formidable hurdle for the development of an HIV-1 vaccine. Elici...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
HIV-1 is a major threat to global health and a vaccine is not yet on the horizon. A successful HIV-1...
Characterizing polyclonal antibody responses via currently available methods is inherently complex a...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
Purpose of review To provide an update on the latest developments in the field of HIV-1 antibody-bas...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
Inducing broad spectrum neutralizing antibodies against challenging pathogens such as HIV-1 is a maj...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...